Syncona appoints Norman Crighton to the Board

SYNC

Syncona Limited (LON:SYNC) has announced the appointment of Norman Crighton to the Board.

Norman Crighton has over 35 years of experience in the investment company industry, spanning investment banking, fund management, and board-level governance. As head of a multinational investment banking department, he advised on the structuring and restructuring of closed-end funds with a focus on sustainable NAV-relative pricing and discount management. As a fund manager, he ran portfolios of investment companies on both a hedged and unhedged basis.

Since 2011, Norman has served as a non-executive director on the boards of nine listed investment companies, being chair of six of them, and one operating company, bringing particular expertise in IPO structuring, corporate governance, and shareholder value creation. He has a strong track record of working with boards and shareholders to narrow persistent discounts and align fund structures with investor expectations.

Norman holds a BA (Hons) in Applied Economics and an MA in Finance and Investment. He currently serves as Chair of RM Infrastructure Income and AVI Japan Opportunity Trust and sits as a Non-Executive Director of Gore Street Energy Storage Fund. Norman previously served as Chair of Harmony Energy Income Trust plc between 2021 and 2025.

On appointment, Norman will join the Company’s Audit Committee, Remuneration Committee and Nomination and Governance Committee.

Melanie Gee, Chair of Syncona Ltd, said: “We are delighted to welcome Norman to the Syncona Board. He brings extensive experience of the investment company sector and has a strong track record of working with Boards to deliver shareholder returns. His expertise will be particularly important to the Company as it focuses on the delivery of our recently approved new Investment Policy and the return of a minimum of £250 million of proceeds to shareholders in a timely manner.”

Norman Crighton said: “I am pleased to be joining the Syncona Board and working with the SIML team to deliver on shareholders’ near-term priorities. I am looking forward to applying my experience in supporting the Company as it seeks to address the discount at which its shares are trading, through the delivery of its recently approved Investment Policy.”

Share on:

Latest Company News

Syncona appoints Norman Crighton to the Board

Syncona has appointed Norman Crighton as a non-executive director, with committee roles and shareholder priorities outlined.

Syncona outlines £250m shareholder return plan and refined investment strategy

Syncona has announced a new set of proposals focused on returning £250 million to shareholders through future portfolio realisations and refining its investment strategy to maximise long-term value.

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options.

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP).

Syncona launches Slingshot to advance early-stage biotech innovations

Syncona Ltd launches Slingshot Therapeutics, investing £12.5 million to advance academic innovations into biotech with a focus on inflammatory diseases.

    Search